Pipeline
Six programs. One set of engineering decisions.
EIG's portfolio spans surgical oncology, radiation protection, endoscopy and wound care. Each program changes the site, the payload and the resorption window; the polymer science, manufacturing route and regulatory logic carry across all of them.
Stage scale · Discovery → Preclinical → Regulatory engagement → Clinical → Market
CancerGuard™ · local therapy at the resection bed
Two cancers, one idea.
Both operations leave behind a compartment where recurrence begins and where a systemic drug arrives late and dilute. The construct and the payload change with the anatomy and the biology; the principle does not.
A bioresorbable scaffold placed into the lumpectomy cavity at breast-conserving surgery, releasing a targeted therapeutic payload into the resection bed over several weeks — turning that bed from a passive surgical space into an active therapeutic zone during the window when microscopic residual disease can proliferate. The scaffold also manages dead space, reduces seroma and maintains the cavity as an imaging landmark for radiotherapy planning.
In active FDA engagement on combination-product classification. De Novo pathway proposed.
A dual-payload construct placed in the pancreatic resection bed at the time of resection. Pancreatic ductal adenocarcinoma carries a five-year survival below 12%, local recurrence after resection is near-universal, systemic therapy penetrates the tumour bed poorly, and these tumours are immunologically cold. The design intent is to address more than one of those problems from a single implant.
Protection, repair and access
Beyond oncology.
A thin-walled bioresorbable intrarectal liner carrying a protective payload in its mucosal-contact layer, placed before external beam prostate radiotherapy for a short dwell window. Perirectal hydrogel spacers reduce rectal dose by changing geometry; they do not address the radiosensitivity of the mucosa that still receives dose. RadiGuard™ is designed to close that biological gap with conformal coverage of the anterior rectal wall, then degrade and pass naturally with no removal procedure. Intended for patients with or without a spacer in place.
In active FDA engagement on combination-product classification. De Novo pathway proposed.
A conformable implant for the retroperitoneal sarcoma resection bed, where local recurrence runs from roughly a third to well over half of patients even after complete resection, and where neoadjuvant radiation has not improved abdominal recurrence-free survival. The architecture is designed to direct release toward the tissue at risk while limiting exposure of adjacent organs, and to give the radiation oncologist landmarks for postoperative planning.
A dual-payload wound patch built around a deliberate two-phase release: an early phase to control contamination at the wound interface, followed by a sustained phase to drive tissue repair, angiogenesis and closure. Existing adjuncts are passive dressings or single-function — they address infection or healing, not both in sequence. Designed to conform to irregular wound geometry and to resorb without removal, which matters in austere and prolonged-field-care settings as much as in the operating room.
A conformal bioresorbable barrier delivered through the scope during the index procedure, expanding and fixating to cover large or irregular mucosal defects after complex polypectomy, EMR or ESD. It provides a barrier in micro-perforation and deep mural injury, isolating luminal contents from exposed submucosa where clips and sutures are incomplete or impractical.
Development stage reflects internal program status and is updated periodically. No program in this portfolio has been cleared or approved for commercial use, none has been studied in humans, and no regulatory pathway or center assignment described here has been determined by FDA. Descriptions state design intent, not demonstrated performance. Payloads, formulations and device specifications are confidential and are shared under agreement.
Interested in a specific program?
Technical packages, preclinical protocols and regulatory status are shared with clinical collaborators, investors and federal partners under appropriate agreement.